Abstract is: Jean-Claude Tardif (born in 1964) is the Director of the Research Center at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. He received his medical degree (MD) in 1987 from the University of Montreal and specialized in cardiology and research in Montreal and Boston until 1994. Dr. Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is also the Scientific Director of the Montreal Health Innovations Coordinating Center (MHICC). His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as early clinical trials and large international randomized clinical trials. Dr. Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases. Dr. Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine, the latter funded by the Network of Centers of Excellence of Canada and which has also been supported by multiple pharmaceutical and biotechnological companies. Dr. Tardif has authored more than 750 scientific articles and has won multiple awards, including the Research Achievement Award of the Canadian Cardiovascular Society, the Distinguished Lecturer Award of the Canadian Institutes for Health Research, the Genesis Award of BIOQuébec (for his outstanding contributions to life sciences), the Armand-Frappier Award of the Government of Québec (the highest scientific honour) and the Margolese National Heart Disorders Prize (for his outstanding contributions to the treatment, amelioration, or cure of heart disorders). Because of his accomplishments, Dr. Tardif was named Fellow of the Canadian Academy of Health Sciences and Fellow of the Royal Society of Canada and was inducted in the Order of Canada (the highest distinction in the country).
| human | Q5 |
| P3280 | BAnQ authority ID | 0000283389 |
| P268 | Bibliothèque nationale de France ID | 13774386k |
| P1670 | Canadiana Authorities ID (former scheme) | 0067J9153 |
| P8179 | Canadiana Name Authority ID | ncf11892797 |
| P1280 | CONOR.SI ID | 114608483 |
| P646 | Freebase ID | /m/0wft4kj |
| P269 | IdRef ID | 075709511 |
| P4491 | Isidore scholar ID | tardif_jean_claude |
| P213 | ISNI | 0000000072669775 |
| P244 | Library of Congress authority ID | n96060467 |
| P949 | National Library of Israel ID (old) | 004703052 |
| P8189 | National Library of Israel J9U ID | 987007384158705171 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 204332400 |
| P1695 | NLP ID (old) | a0000003116599 |
| P1015 | NORAF ID | 6092861 |
| P1207 | NUKAT ID | n2011111175 |
| P496 | ORCID iD | 0000-0002-8200-8983 |
| P8951 | Order of Canada recipient ID | 146-11105 |
| 146-11105 | ||
| P7293 | PLWABN ID | 9810696101405606 |
| P2038 | ResearchGate profile ID | Jean-Claude_Tardif |
| P1153 | Scopus author ID | 35399980400 |
| P214 | VIAF ID | 316014078 |
| P10832 | WorldCat Entities ID | E39PBJyxg3bwrhfRF6cMg96tKd |
| P1416 | affiliation | Montreal Heart Institute | Q3151984 |
| Faculté de médecine de l'Université de Montréal | Q7896819 | ||
| Département de médecine de l'Université de Montréal | Q113483482 | ||
| P166 | award received | Order of Canada | Q99700 |
| Prix Armand-Frappier | Q3404367 | ||
| P27 | country of citizenship | Canada | Q16 |
| P108 | employer | Université de Montréal | Q392189 |
| P734 | family name | Tardif | Q37521977 |
| Tardif | Q37521977 | ||
| Tardif | Q37521977 | ||
| P735 | given name | Jean-Claude | Q3164791 |
| Jean-Claude | Q3164791 | ||
| P1412 | languages spoken, written or signed | French | Q150 |
| P463 | member of | Royal Society of Canada | Q94301 |
| P106 | occupation | university teacher | Q1622272 |
| cardiologist | Q3264451 | ||
| P39 | position held | full professor | Q25339110 |
| P21 | sex or gender | male | Q6581097 |
| Q57418636 | A Comprehensive Evaluation of the Genetic Architecture of Sudden Cardiac Arrest |
| Q52590498 | A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. |
| Q86890448 | A comparison between the principal stress direction and collagen fiber orientation in coronary atherosclerotic plaque fibrous caps |
| Q99638179 | A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy |
| Q97640029 | A genetic model of ivabradine recapitulates results from randomized clinical trials |
| Q48659496 | A look into the future of cardiology: perspectives from the Montreal Heart Institute. |
| Q40549451 | A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine |
| Q38389477 | A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients |
| Q50867744 | A numerical investigation of the functionality of coronary bifurcation lesions with respect to lesion configuration and stenosis severity. |
| Q53022569 | A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. |
| Q53820814 | A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. |
| Q38497869 | A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. |
| Q43515783 | A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass |
| Q47404908 | A robust 3-D IVUS transducer tracking using single-plane cineangiography |
| Q51281320 | A single Mediterranean meal does not impair postprandial flow-mediated dilatation in healthy men with subclinical metabolic dysregulations. |
| Q39390059 | A single bout of high-intensity interval exercise does not increase endothelial or platelet microparticles in stable, physically fit men with coronary heart disease |
| Q57239695 | A survey of the personalized medicine landscape |
| Q37429273 | A winter's tale: report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium |
| Q59349318 | ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) |
| Q37869631 | Absence of association between infectious agents and endothelial function in healthy young men. |
| Q37098363 | Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). |
| Q110788205 | Abstract 17214: Differential Relationships Between Serum Cholesterol Efflux Capacities Measured From Three Cell Models and Coronary Artery Disease Status in the Montreal Heart Institute Biobank |
| Q43280381 | Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome |
| Q51795410 | Acute intraoperative effect of intravenous amiodarone on right ventricular function in patients undergoing valvular surgery. |
| Q56967201 | Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome |
| Q74476302 | Advanced contour detection for three-dimensional intracoronary ultrasound: a validation--in vitro and in vivo |
| Q38382574 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. |
| Q79151492 | Alterations in the endothelial G-protein coupled receptor pathway in epicardial arteries and subendocardial arterioles in compensated left ventricular hypertrophy |
| Q37060322 | Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial |
| Q92231032 | An N-/L-type calcium channel blocker, cilnidipine, suppresses autonomic, electrical, and structural remodelling associated with atrial fibrillation |
| Q38032616 | An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels |
| Q51995088 | Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. |
| Q36328855 | Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial |
| Q36997647 | Anti-inflammatory drugs and atherosclerosis |
| Q43733779 | Anti-inflammatory drugs and the heart |
| Q104134528 | Anti-inflammatory therapy for COVID-19 infection: the case for colchicine |
| Q36026006 | Antioxidants and atherosclerosis: emerging drug therapies |
| Q36405142 | Antioxidants: the good, the bad and the ugly |
| Q40182253 | Aortic coarctation and the retinal microvasculature |
| Q42373755 | Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice |
| Q89145871 | Apolipoprotein A-I proteolysis in aortic valve stenosis: role of cathepsin S |
| Q38073879 | Apolipoprotein B antisense inhibition--update on mipomersen |
| Q52647430 | Applicability and accuracy of pretest probability calculations implemented in the NICE clinical guideline for decision making about imaging in patients with chest pain of recent onset. |
| Q36026834 | Are Canadian guidelines for cholesterol lowering in high-risk patients optimal? |
| Q37338935 | Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance. |
| Q42785171 | Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. |
| Q36255340 | Assessment of Inter-Expert Variability and of an Automated Segmentation Method of 40 and 60 MHz IVUS Images of Coronary Arteries |
| Q38757917 | Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery |
| Q92528135 | Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events |
| Q46744131 | Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. |
| Q92575115 | Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial |
| Q81371288 | Atherosclerosis imaging |
| Q38067905 | Atherosclerosis imaging and the Canadian Atherosclerosis Imaging Network. |
| Q84423689 | Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy |
| Q44802448 | Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. |
| Q48013299 | Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model |
| Q85263905 | Atrial fibrillation-associated remodeling does not promote atrial thrombus formation in canine models |
| Q92086655 | Autoantibody Signature in Cardiac Arrest |
| Q91679977 | Automatic IVUS lumen segmentation using a 3D adaptive helix model |
| Q48471247 | Baseline regional cerebral oxygen saturation correlates with left ventricular systolic and diastolic function |
| Q36242530 | Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome. |
| Q42952222 | Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure |
| Q90578720 | Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. |
| Q98387120 | Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches |
| Q38071328 | Biologics and the cardiovascular system: a double-edged sword |
| Q91279739 | Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation |
| Q83296161 | Biventricular diastolic filling patterns after coronary artery bypass graft surgery |
| Q92384653 | Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design |
| Q92535593 | Blood pressure and burden of hypertension in Cameroon, a microcosm of Africa: a systematic review and meta-analysis of population-based studies |
| Q100524626 | Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial |
| Q47723936 | Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study |
| Q51167013 | CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib. |
| Q50633334 | CKM and LILRB5 are associated with serum levels of creatine kinase. |
| Q53832400 | CKing Precision in the Interpretation of Diagnostic Biomarkers. |
| Q57029923 | COMMANDER HF - A Trial and an Answer |
| Q37070091 | Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease |
| Q79817185 | Can ACAT inhibition limit the progression of atherosclerosis in patients with coronary artery disease? |
| Q59186843 | Canada Acute Coronary Syndrome Risk Score: A new risk score for early prognostication in acute coronary syndromes |
| Q38234223 | Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease |
| Q51116293 | Cap buckling as a potential mechanism of atherosclerotic plaque vulnerability. |
| Q28301432 | Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training |
| Q38071327 | Cardiac consequences of anti-inflammatory drugs in experimental models |
| Q92498681 | Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits |
| Q36399467 | Cardiac investigation in patients with diabetes |
| Q47746637 | Cardiac pathways distinguish two epistatic modules enacting BP quantitative trait loci and candidate gene analysis |
| Q51008532 | Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: insights from the AF-CHF echocardiographic sub-study. |
| Q30755348 | Cardiometabolic and traditional cardiovascular risk factors and their potential impact on macrovascular and microvascular function: preliminary data |
| Q37860653 | Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group |
| Q47258313 | Cardioprotection--time to take into account clinical complexity: the case of antiplatelet agents : editorial to "two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts" by Xi-Ming Yang et al. |
| Q38404786 | Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients |
| Q58480971 | Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia |
| Q38048834 | Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges |
| Q39427120 | Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study |
| Q52568923 | Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. |
| Q111430015 | Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking |
| Q95702155 | Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease |
| Q43741451 | Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry |
| Q45905189 | Characterization of fracture toughness exhaustion in pig aorta. |
| Q46231225 | Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc |
| Q92153368 | Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry |
| Q79743980 | Circulating 4-hydroxynonenal-protein thioether adducts assessed by gas chromatography-mass spectrometry are increased with disease progression and aging in spontaneously hypertensive rats |
| Q52575994 | Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. |
| Q37539268 | Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure |
| Q37868817 | Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies |
| Q39462891 | Clinical outcomes and economic impact of transcatheter mitral leaflet repair in heart failure patients |
| Q36999874 | Clinical results of I(f) current inhibition by ivabradine |
| Q35088538 | Clinical results with AGI-1067: a novel antioxidant vascular protectant |
| Q38038418 | Clinical value of drugs targeting inflammation for the management of coronary artery disease |
| Q46701076 | Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study |
| Q73310559 | Cloth tears in asymptomatic survivors of aortic valve replacement with starr-edwards prostheses: detection by transesophageal echocardiography |
| Q36851336 | Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease |
| Q102070452 | Colchicine for Secondary Cardiovascular Prevention in Coronary Disease |
| Q100733449 | Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q103828841 | Colchicine reduces lung injury in experimental acute respiratory distress syndrome |
| Q38071323 | Colchicine: an old wine in a new bottle? |
| Q43760484 | Combining distinctive and novel loci doubles BP reduction, reverses diastolic dysfunction and mitigates LV hypertrophy |
| Q37666261 | Common variation in fatty acid metabolic genes and risk of incident sudden cardiac arrest |
| Q97680379 | Comparison of Atrial Remodeling Caused by Sustained Atrial Flutter Versus Atrial Fibrillation |
| Q35100135 | Comparison of genotype clustering tools with rare variants |
| Q80049580 | Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression |
| Q43086527 | Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study |
| Q62682520 | Comprehensive and Reproducible Untargeted Lipidomic Workflow Using LC-QTOF Validated for Human Plasma Analysis |
| Q41878976 | Computed tomographic coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE HF Project 1-C). |
| Q91684128 | Conjugation of multivalent ligands to gold nanoshells and designing a dual modality imaging probe |
| Q112572309 | Construction of a femininity score in the UK Biobank and its association with angina diagnosis prior to myocardial infarction |
| Q45019433 | Coronary flow velocity reserve does not correlate with TIMI frame count in patients undergoing non-emergency percutaneous coronary intervention |
| Q28218905 | Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management |
| Q36732931 | Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. |
| Q56963201 | Correction to: Applicability and accuracy of pretest probability calculations implemented in the NICE clinical guideline for decision making about imaging in patients with chest pain of recent onset |
| Q42502463 | Correction: The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study |
| Q28219483 | Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease |
| Q74695824 | Cutting and stenting in a heavily calcified left anterior descending artery lesion |
| Q90117212 | Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease |
| Q33867662 | Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys |
| Q33772454 | Damming the genomic data flood using a comprehensive analysis and storage data structure |
| Q82278727 | De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? |
| Q46159102 | Defensiveness and metabolic syndrome: impact of sex and age. |
| Q34441746 | Defining the role of common variation in the genomic and biological architecture of adult human height |
| Q44164931 | Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial |
| Q85788211 | Detailed characterization of microRNA changes in a canine heart failure model: Relationship to arrhythmogenic structural remodeling |
| Q44391469 | Detection of myocardial perfusion abnormalities after a recent acute coronary syndrome by quantitative Levovist myocardial contrast echocardiography: comparison with 99m Tc-Myoview SPECT imaging. |
| Q48252756 | Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea |
| Q39142325 | Development of a broad-based ADME panel for use in pharmacogenomic studies |
| Q51015329 | Development of a new bioactivatable fluorescent probe for quantification of apolipoprotein A-I proteolytic degradation in vitro and in vivo. |
| Q46310610 | Development of a photoacoustic, ultrasound and fluorescence imaging catheter for the study of atherosclerotic plaque |
| Q101466636 | Diabetes, Brain Infarcts, Cognition and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study |
| Q37757979 | Diabetic dyslipidemia: extending the target beyond LDL cholesterol |
| Q64904319 | Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: meta-analysis of individual patient data. |
| Q33790534 | Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies |
| Q60448697 | Dietary fatty acids and oxidative stress in the heart mitochondria |
| Q38948558 | Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry |
| Q42926780 | Differential Response of Endothelial Cells to Simvastatin When Conditioned with Steady, Non-Reversing Pulsatile or Oscillating Shear Stress |
| Q43291613 | Differential distribution of 4-hydroxynonenal adducts to sulfur and nitrogen residues in blood proteins as revealed using Raney nickel and gas chromatography-mass spectrometry |
| Q84114156 | Difficult and complex separation from cardiopulmonary bypass in high-risk cardiac surgical patients: a multicenter study |
| Q37930145 | Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature |
| Q90639013 | Discordances between predicted and actual risk in obese patients with suspected cardiac ischaemia |
| Q75244969 | Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure |
| Q82020746 | Distinct genomic replacements from Lewis correct diastolic dysfunction, attenuate hypertension, and reduce left ventricular hypertrophy in Dahl salt-sensitive rats |
| Q99731227 | Distorting effect of immortal time bias on the association between catheter ablation for atrial fibrillation and incident stroke: Caveat Emptor |
| Q91041019 | Does low-density lipoprotein cholesterol induce inflammation? If so, does it matter? Current insights and future perspectives for novel therapies |
| Q34141982 | Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria? |
| Q49113432 | Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs |
| Q79784441 | Dynamic right ventricular outflow tract obstruction in cardiac surgery |
| Q87968893 | Early Detection of Cardiac Allograft Vasculopathy and Long-Term Risk After Heart Transplantation |
| Q48190240 | Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice |
| Q44204250 | Economic impact of contrast stress echocardiography on the diagnosis and initial treatment of patients with suspected coronary artery disease |
| Q46807065 | Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril |
| Q38380431 | Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]). |
| Q110902639 | Effect of Perindopril on Atrial Fibrillation Recurrence and Burden: Results of the Canadian Trial of Atrial Fibrillation (CTAF)-2 |
| Q34660831 | Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial |
| Q80031212 | Effect of aortic valve replacement for aortic stenosis on severity of mitral regurgitation |
| Q47333087 | Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound |
| Q47848804 | Effect of inhibition of the Na+/H+ exchanger with cariporide on left ventricular function in acute coronary syndromes: results from the echocardiographic substudy of the GUARDIAN trial. |
| Q48568149 | Effect of intravenous nitroglycerin on cerebral saturation in high-risk cardiac surgery |
| Q46672523 | Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. |
| Q43056627 | Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. |
| Q48149488 | Effect of stenosis eccentricity on the functionality of coronary bifurcation lesions-a numerical study. |
| Q38487137 | Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial |
| Q28295023 | Effect of torcetrapib on the progression of coronary atherosclerosis |
| Q44878173 | Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study. |
| Q34501729 | Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial |
| Q85247112 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of observational studies |
| Q44302074 | Effects of AGI-1067 and probucol after percutaneous coronary interventions. |
| Q92535610 | Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT |
| Q87132714 | Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery: SELECT-CABG Trial |
| Q46064528 | Effects of anesthetic induction in patients with diastolic dysfunction |
| Q46491497 | Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure |
| Q44565514 | Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). |
| Q34309967 | Effects of dalcetrapib in patients with a recent acute coronary syndrome |
| Q44218875 | Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial |
| Q48582432 | Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study |
| Q43926545 | Effects of plaque composition on vascular remodelling after angioplasty in the MultiVitamins and Probucol (MVP) trial |
| Q80392226 | Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study |
| Q38398332 | Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial |
| Q81309928 | Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction |
| Q46353085 | Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design |
| Q34631911 | Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy |
| Q46576382 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial |
| Q38384596 | Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial. |
| Q46860069 | Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial |
| Q45144400 | Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions |
| Q79533790 | Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial |
| Q34644974 | Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial |
| Q38460350 | Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial |
| Q91304576 | Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction |
| Q38391329 | Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial |
| Q37495353 | Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris |
| Q28276346 | Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina |
| Q43183736 | Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus |
| Q37112685 | Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial |
| Q58768970 | Elevated level of lecithin:cholesterol acyltransferase (LCAT) is associated with reduced coronary atheroma burden |
| Q38084460 | Emerging anti-inflammatory therapies for atherosclerosis |
| Q42788509 | Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology? |
| Q44456364 | Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials |
| Q44025903 | Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure |
| Q44357144 | Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). |
| Q84615330 | Endothelial cell morphologic response to asymmetric stenosis hemodynamics: effects of spatial wall shear stress gradients |
| Q83272573 | Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study |
| Q50082577 | Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. |
| Q42342101 | Erratum: Genetic loci associated with heart rate variability and their effects on cardiac disease risk |
| Q40630347 | Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular E |
| Q42642098 | Evaluation of Ventricular dP/dt Before and After Open Heart Surgery Using Transesophageal Echocardiography |
| Q37419421 | Evaluation of coronary atheroma by 64-slice multidetector computed tomography: Comparison with intravascular ultrasound and angiography |
| Q44762986 | Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans |
| Q34655950 | Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. |
| Q91468741 | Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis |
| Q90281781 | Exchange protein activated by cyclic-adenosine monophosphate (Epac) regulates atrial fibroblast function and controls cardiac remodelling |
| Q54378720 | Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained β-adrenergic activation in guinea pig hearts. |
| Q42266383 | Exercise above the ischemic threshold and serum markers of myocardial injury |
| Q60297002 | Exome chip meta-analysis fine maps causal variants and elucidates the genetic architecture of rare coding variants in smoking and alcohol use |
| Q45071322 | Exome-wide association study of plasma lipids in >300,000 individuals |
| Q84553404 | Expression and recovery of biologically active recombinant Apolipoprotein AI(Milano) from transgenic safflower (Carthamus tinctorius) seeds |
| Q28546212 | Expression of phosphoinositide-specific phospholipase C isoforms in native endothelial cells |
| Q47779646 | Expression of the Frizzled receptors and their co-receptors in calcified human aortic valves |
| Q81851095 | External beam radiation to prevent restenosis after superficial femoral artery balloon angioplasty |
| Q36588857 | FTO genotype is associated with phenotypic variability of body mass index |
| Q36320627 | Fabricating Water Dispersible Superparamagnetic Iron Oxide Nanoparticles for Biomedical Applications through Ligand Exchange and Direct Conjugation |
| Q45935605 | Fast-marching segmentation of three-dimensional intravascular ultrasound images: a pre- and post-intervention study. |
| Q37117839 | Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease |
| Q51474729 | Fasting plasma glucose predicts survival and angiographic progression in high-risk postmenopausal women with coronary artery disease. |
| Q37193704 | Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial |
| Q57446571 | Fish Oil for the Reduction of Atrial Fibrillation Recurrence, Inflammation, and Oxidative Stress |
| Q91177628 | From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants |
| Q84977263 | Functional effects of adiponectin on endothelial progenitor cells |
| Q46293134 | Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease |
| Q92020049 | Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease |
| Q30313100 | Genetic loci associated with heart rate variability and their effects on cardiac disease risk |
| Q34534212 | Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes |
| Q30844230 | Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry |
| Q40036505 | Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform--from R&D to the clinic |
| Q38630971 | HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology |
| Q54634220 | HDL and cardiovascular risk: is cholesterol in particle subclasses relevant? |
| Q50094243 | HDL biogenesis revisited: how desmocollin-1 could sabotage reverse cholesterol transport in the arterial wall |
| Q53111599 | HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits. |
| Q49507454 | Heart Rate Response in Spectators of the Montreal Canadiens Hockey Team |
| Q38426792 | Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes |
| Q40615353 | Heart rate and adverse outcomes in patients with atrial fibrillation: A combined AFFIRM and AF-CHF substudy |
| Q28730142 | Heart rate and use of beta-blockers in stable outpatients with coronary artery disease |
| Q37497745 | Heart rate as a treatable cardiovascular risk factor |
| Q44798213 | Heart rate recovery after exercise and long-term prognosis in patients with coronary artery disease |
| Q42760642 | Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. |
| Q36579074 | Heart rate slowing versus other pharmacological antianginal strategies |
| Q36980867 | Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice |
| Q46094214 | Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats |
| Q40369900 | Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease |
| Q37350172 | High-density lipoprotein/apolipoprotein A-I infusion therapy |
| Q96121475 | High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential |
| Q52805055 | Homeostasis Model Assessment of Insulin Resistance and Survival in Patients with Diabetes and Acute Coronary Syndrome. |
| Q47327388 | Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci |
| Q39763138 | Hybrid FMT-MRI applied to in vivo atherosclerosis imaging |
| Q90650768 | Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome |
| Q114008366 | Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG |
| Q37860655 | Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). |
| Q33954488 | Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals |
| Q73833667 | Identification of atrial tissue in pulmonary veins using intravascular ultrasound |
| Q36968428 | Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders |
| Q81796533 | Image based biomechanics of coronary plaque |
| Q36434865 | Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. |
| Q37876592 | Imaging biomarkers in atherosclerosis trials |
| Q51945900 | Imaging biomarkers of atherosclerosis. |
| Q98474769 | Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial |
| Q61856298 | Impact of an invasive strategy in the elderly hospitalized with acute coronary syndrome with emphasis on the nonagenarians |
| Q28541044 | Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients |
| Q46625599 | Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). |
| Q47850246 | Impact of hyperventilation and apnea on myocardial oxygenation in patients with obstructive sleep apnea - An oxygenation-sensitive CMR study |
| Q35735988 | Impact of regular physical activity on weekly warfarin dose requirement |
| Q93264351 | Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease |
| Q54423753 | Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. |
| Q98578817 | In Memoriam - Martial G. Bourassa (1931-2020) |
| Q64107080 | In Vivo Near-Infrared Fluorescence Imaging of Atherosclerosis Using Local Delivery of Novel Targeted Molecular Probes |
| Q45753902 | In vivo validation of a catheter-based near-infrared spectroscopy system for detection of lipid core coronary plaques: initial results of the SPECTACL study |
| Q45424178 | Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry |
| Q81570922 | Incidence and significance of abnormal hepatic venous Doppler flow velocities before cardiac surgery |
| Q44129353 | Incidence of stent under-deployment as a cause of in-stent restenosis in long stents |
| Q91980409 | Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry |
| Q50077217 | Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus |
| Q94493944 | Increasing Dietary Vitamin K Intake Stabilizes Anticoagulation Therapy in Warfarin-Treated Patients with a History of Instability: A 24-week Randomized Controlled Trial (OR36-04-19) |
| Q30589479 | Individual patient data meta-analysis for the clinical assessment of coronary computed tomography angiography: protocol of the Collaborative Meta-Analysis of Cardiac CT (CoMe-CCT). |
| Q53482613 | Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. |
| Q89477733 | Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease |
| Q38786058 | Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis |
| Q86987550 | Inflammation and the heart - prime time for new therapeutic approaches |
| Q36697918 | Inhaled milrinone: a new alternative in cardiac surgery? |
| Q90616765 | Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response |
| Q107466874 | Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib |
| Q44616491 | Institutional profile: the Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute |
| Q46777642 | Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). |
| Q111430019 | International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study |
| Q35739807 | Intravascular ultrasound assessment of atherosclerosis |
| Q91379256 | Investigational drugs in development for hypertriglyceridemia: a coming-of-age story |
| Q38161896 | Investigational drugs targeting cardiac fibrosis |
| Q43938539 | Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment? |
| Q43575113 | Is patient-prosthesis mismatch a perioperative predictor of long-term mortality after aortic valve replacement? |
| Q46457609 | Is there an association between coronary atherosclerosis and airway responsiveness? |
| Q51590601 | Ivabradine and metoprolol differentially affect cardiac glucose metabolism despite similar heart rate reduction in a mouse model of dyslipidemia. |
| Q38769814 | Ivabradine for the treatment of chronic heart failure |
| Q53262277 | Ivabradine in stable coronary artery disease without clinical heart failure. |
| Q41906203 | Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts |
| Q37184428 | Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases |
| Q33973963 | Ivabradine: the evidence of its therapeutic impact in angina |
| Q55036030 | JAK-STAT signaling and the atrial fibrillation promoting fibrotic substrate. |
| Q39652316 | Laminar shear stress prevents simvastatin-induced adhesion molecule expression in cytokine activated endothelial cells. |
| Q30276495 | Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases |
| Q48661682 | Left and right ventricular diastolic dysfunction as predictors of difficult separation from cardiopulmonary bypass |
| Q38511039 | Lipid effects and cardiovascular disease risk associated with glucose-lowering medications. |
| Q86055738 | Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist |
| Q50793133 | Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. |
| Q88674001 | Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned? |
| Q92152779 | Lipoprotein (a), arterial inflammation, and PCSK9 inhibition |
| Q57239641 | Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis |
| Q92362002 | Lipoprotein(a) Reduction in Persons with Cardiovascular Disease |
| Q91813705 | Living alone and cardiovascular disease outcomes |
| Q41078909 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome |
| Q90027023 | Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry |
| Q81537671 | Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease |
| Q81397051 | Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries |
| Q36909397 | Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy |
| Q42478282 | Loss of cardiomyocyte integrin-linked kinase produces an arrhythmogenic cardiomyopathy in mice |
| Q93152530 | Low-Dose Colchicine after Myocardial Infarction. Reply |
| Q83108462 | Low-cost three-dimensional imaging system combining fluorescence and ultrasound |
| Q48247128 | MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart |
| Q92553306 | MK5 haplodeficiency decreases collagen deposition and scar size during post-myocardial infarction wound repair |
| Q91691268 | Magnetic resonance imaging/fluorescence dual modality protocol using designed phosphonate ligands coupled to superparamagnetic iron oxide nanoparticles |
| Q88344098 | Management of Acute Coronary Syndromes |
| Q54273402 | Management of acute coronary syndromes. |
| Q38144350 | Management of pericarditis and myocarditis: could heart-rate-reducing drugs hold a promise? |
| Q40573539 | Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population |
| Q43155209 | Mechanical characterization of atherosclerotic arteries using finite-element modeling: feasibility study on mock arteries |
| Q91076264 | Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes |
| Q30276013 | Meta-analysis of genome-wide association studies of HDL cholesterol response to statins |
| Q63352621 | Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci |
| Q91683362 | Miktoarm star conjugated multifunctional gold nanoshells: synthesis and an evaluation of biocompatibility and cellular uptake |
| Q80548272 | Milrinone enhances systolic, but not diastolic function during coronary artery bypass grafting surgery |
| Q84575373 | Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial |
| Q78001237 | Mitral Doppler indices are superior to two-dimensional echocardiographic and hemodynamic variables in predicting responsiveness of cardiac output to a rapid intravenous infusion of colloid |
| Q34128043 | Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. |
| Q35637464 | Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2 Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries |
| Q62127932 | Near-infrared spectroscopy for cardiovascular risk assessment? Not ready for prime time |
| Q34043689 | Neutrophil adhesion on endothelial cells in a novel asymmetric stenosis model: effect of wall shear stress gradients |
| Q38106677 | New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels |
| Q50606987 | Nonsense mutations in BAG3 are associated with early-onset dilated cardiomyopathy in French Canadians. |
| Q39153192 | Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery |
| Q57822878 | Novel Pathogenesis of Hypertension and Diastolic Dysfunction Caused by M3R (Muscarinic Cholinergic 3 Receptor) Signaling |
| Q38445578 | Novel anti-inflammatory therapies for the treatment of atherosclerosis |
| Q39177005 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality |
| Q35099855 | Optimisation of reference genes for gene-expression analysis in a rabbit model of left ventricular diastolic dysfunction |
| Q33627020 | Optimus Primer: A PCR enrichment primer design program for next-generation sequencing of human exonic regions |
| Q91407753 | Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation |
| Q91501536 | PBI-4050 Reduces Pulmonary Hypertension, Lung fibrosis and Right Ventricular Dysfunction in Heart Failure |
| Q57315735 | PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION |
| Q101226747 | Paracrine signalling by cardiac calcitonin controls atrial fibrogenesis and arrhythmia |
| Q46235968 | Perioperative THR-184 and AKI after Cardiac Surgery |
| Q43227077 | Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery |
| Q34453666 | Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins |
| Q47750262 | Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies |
| Q38800886 | Pharmacogenomic approaches to lipid-regulating trials |
| Q34457943 | Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib |
| Q53820590 | Pharmacogenomics of blood lipid regulation. |
| Q38696985 | Pharmacogenomics to Revive Drug Development in Cardiovascular Disease |
| Q38533622 | Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms |
| Q35587196 | Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies |
| Q86476800 | Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab--preclinical and clinical studies |
| Q43195602 | Physiological stress responses in defensive individuals: age and sex matter |
| Q38861666 | Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users |
| Q30276496 | Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals |
| Q51372044 | Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. |
| Q47121697 | Polygenic determinants in extremes of high-density lipoprotein cholesterol |
| Q57239659 | Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians |
| Q79946798 | Poor correlation between hemodynamic and echocardiographic indexes of left ventricular performance in the operating room and intensive care unit |
| Q97678223 | Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure |
| Q38875367 | Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome |
| Q64964546 | Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. |
| Q60514264 | Precision medicine to change the landscape of cardiovascular drug development |
| Q57239663 | Predicting Statin Induced Muscle Toxicity |
| Q91319962 | Predictive Model for High-Risk Coronary Artery Disease |
| Q47625297 | Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes |
| Q48348556 | Preliminary experience in the use of preoperative echo-guided left stellate ganglion block in patients undergoing cardiac surgery |
| Q30841815 | Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry |
| Q111430018 | Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities |
| Q36575465 | Prevention challenges: the era of atherosclerosis regression |
| Q35631201 | Prevention of restenosis with antioxidants: mechanisms and implications |
| Q50897412 | Profile: Montreal Cardiology Institute, Canada. |
| Q38378366 | Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). |
| Q33762797 | Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve |
| Q47177885 | Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q62839973 | Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution |
| Q36176383 | Psychological Profiles in the Prediction of Leukocyte Telomere Length in Healthy Individuals. |
| Q92503516 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q51762287 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q51779676 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q64082954 | PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension |
| Q101407368 | Pulmonary Vein Stenosis after Atrial Fibrillation Ablation: Insights from the Adenosine following pulmonary Vein Isolation to target dormant Conduction Elimination Trial |
| Q33754161 | Pulmonary hypertension in cardiac surgery |
| Q38398157 | Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy |
| Q80333383 | Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials |
| Q100429873 | REDUCE-IT INTERIM: Accumulation of Data Across Prespecified Interim Analyses to Final Results |
| Q91213477 | REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States |
| Q61070267 | Racial differences of lipoprotein subclass distributions in postmenopausal women |
| Q90846907 | Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype |
| Q46915557 | Randomized trial of hormone therapy in women after coronary bypass surgery. Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries |
| Q34477657 | Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy |
| Q39932114 | Rapid pacing rotational angiography with three-dimensional reconstruction: use and benefits in structural heart disease interventions |
| Q29583867 | Rare and low-frequency coding variants alter human adult height |
| Q28239018 | Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits |
| Q33578422 | Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial |
| Q43230598 | Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. |
| Q52654541 | Rationale, design and preliminary results of the Quebec Warfarin Cohort Study. |
| Q40948527 | Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo |
| Q38754352 | Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease |
| Q57243337 | Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): A randomized, double-blind, placebo-controlled trial of i |
| Q36087571 | Rationale, design, and methods for Canadian alliance for healthy hearts and minds cohort study (CAHHM) - a Pan Canadian cohort study |
| Q46564706 | Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4). |
| Q51008008 | Real-time compared to off-line evaluation of segmental wall motion abnormalities with transesophageal echocardiography using dobutamine stress testing. |
| Q49920018 | Recurrent Cardiovascular Events in Survivors of Myocardial Infarction With ST-Segment Elevation (from the AMI-QUEBEC Study). |
| Q90002937 | Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging-Detected Vascular Brain Injury |
| Q92790940 | Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles |
| Q101223685 | Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC |
| Q38019423 | Regression of atherosclerosis |
| Q73801210 | Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease |
| Q46855765 | Relation of myocardial perfusion defects and nonsignificant coronary lesions by angiography with insights from intravascular ultrasound and coronary pressure measurements |
| Q48445392 | Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study |
| Q90312762 | Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease |
| Q47678757 | Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension |
| Q47425573 | Remodeling is a more important determinant of lumen size than atheroma burden in left main coronary artery disease |
| Q87351812 | Renin-angiotensin system inhibition and secondary cardiovascular prevention |
| Q57243457 | Reply |
| Q84802755 | Reproducibility of near-infrared spectroscopy parameters measured during brachial artery occlusion and reactive hyperemia in healthy men |
| Q88394557 | Response to Hjuler et al |
| Q57239635 | Resting heart rate as a predictor of aortic valve stenosis progression |
| Q36919145 | Resting heart rate in cardiovascular disease |
| Q34774214 | Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes? |
| Q60952860 | Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration |
| Q80506852 | Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension |
| Q80876154 | Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure |
| Q93129879 | Right Atrial Mechanisms of Atrial Fibrillation in a Rat Model of Right Heart Disease |
| Q48083041 | Right Ventricular Depression After Cardiopulmonary Bypass for Valvular Surgery |
| Q40204044 | Right ventricular myocardial performance index predicts perioperative mortality or circulatory failure in high-risk valvular surgery |
| Q34296015 | Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. |
| Q38376243 | Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus |
| Q51021597 | Role of Noncanonical Wnt Signaling Pathway in Human Aortic Valve Calcification. |
| Q54368805 | Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. |
| Q34089553 | Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure |
| Q92907791 | Role of atrial arrhythmia and ventricular response in atrial fibrillation induced atrial remodeling |
| Q83995529 | Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy |
| Q33592854 | Routine versus selective cardiac magnetic resonance in non-ischemic heart failure - OUTSMART-HF: study protocol for a randomized controlled trial (IMAGE-HF (heart failure) project 1-B) |
| Q34196711 | Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registry |
| Q34120778 | Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial |
| Q48320888 | Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). |
| Q51152249 | Segmentation method of intravascular ultrasound images of human coronary arteries. |
| Q87232642 | Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients |
| Q57137897 | Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines |
| Q92548150 | Simple risk models to predict cardiovascular death in patients with stable coronary artery disease |
| Q47428896 | Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction |
| Q91207360 | Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain |
| Q90417297 | Site qualification and clinical interpretation standards for 99mTc-SPECT perfusion imaging in a multi-center study of MITNEC (Medical Imaging Trials Network of Canada) |
| Q44527433 | Specific alterations of endothelial signal transduction pathways of porcine epicardial coronary arteries in left ventricular hypertrophy |
| Q89841467 | Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib |
| Q92522162 | Subsequent Event Risk in Individuals With Established Coronary Heart Disease |
| Q51169086 | Surface engineering of SPIONs: role of phosphonate ligand multivalency in tailoring their efficacy. |
| Q40419556 | Sustained elevation of serum CD40 ligand levels one month after coronary angioplasty predicts angiographic restenosis |
| Q35063167 | Symptomatic myocardial bridges: overview of ischemic mechanisms and current diagnostic and treatment strategies. |
| Q37648324 | Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease |
| Q45225784 | T-type calcium current contributes to escape automaticity and governs the occurrence of lethal arrhythmias after atrioventricular block in mice |
| Q50848643 | TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. |
| Q41866389 | Targeted ablation of ILK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure |
| Q83953786 | Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction |
| Q37073583 | Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring--further insights from SOLVD. |
| Q91375665 | Ten-Year Statin Adherence in Survivors of ST-Segment Elevation Myocardial Infarction |
| Q28597672 | Testing the role of predicted gene knockouts in human anthropometric trait variation |
| Q44543607 | Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model |
| Q104283874 | The Canadian Alliance for Healthy Hearts and Minds: How Well Does It Reflect the Canadian Population? |
| Q34673513 | The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study |
| Q98953154 | The Polygenic and Monogenic Basis of Blood Traits and Diseases |
| Q26743433 | The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy |
| Q92200173 | The Use of Random Forests to Classify Amyloid Brain PET |
| Q94520724 | The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score |
| Q36066019 | The drug-based pipeline against restenosis |
| Q35762441 | The effect of simvastatin treatment on endothelial cell response to shear stress and tumor necrosis factor alpha stimulation. |
| Q44816801 | The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women |
| Q38967759 | The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial |
| Q110986933 | The impact of reporting magnetic resonance imaging incidental findings in the Canadian alliance for healthy hearts and minds cohort |
| Q99633821 | The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodeling in experimental right heart disease |
| Q50223187 | The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model |
| Q46916351 | The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. |
| Q47887411 | The relation between hostility and concurrent levels of inflammation is sex, age, and measure dependent |
| Q38061799 | The role of oxidative stress in postprandial endothelial dysfunction |
| Q37576100 | The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease |
| Q60448704 | Thermal sensitivity of cardiac mitochondrial metabolism in an ectothermic species from a cold environment, Atlantic wolffish (Anarhichas lupus) |
| Q60448707 | Thermal sensitivity of oxidative phosphorylation in rat heart mitochondria: Does pyruvate dehydrogenase dictate the response to temperature? |
| Q104757475 | Thermal tolerance and fish heart integrity: fatty acids profiles as predictors of species resilience |
| Q47666648 | Thermal tolerance and thermal sensitivity of heart mitochondria: Mitochondrial integrity and ROS production |
| Q51530796 | Three-dimensional trajectory assessment of an IVUS transducer from single-plane cineangiograms: a phantom study. |
| Q46539901 | Thrombospondin-1-Derived Peptide RFYVVMWK Improves the Adhesive Phenotype of CD34+ Cells From Atherosclerotic Patients With Type 2 Diabetes. |
| Q98829737 | Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) |
| Q36043171 | Trait Hostility and Acute Inflammatory Responses to Stress in the Laboratory |
| Q98953152 | Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations |
| Q36909069 | Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation |
| Q43853263 | Transient right internal thoracic arterial graft kink related to respiratory movements: documentation of its existence, relevance and proposed management |
| Q74615657 | Transmural action potential and ionic current remodeling in ventricles of failing canine hearts |
| Q51291884 | Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. |
| Q38375421 | Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. |
| Q74535586 | Two-year angiographic follow-up of intracoronary Sr90 therapy for restenosis prevention after balloon angioplasty |
| Q45731874 | Unique quantitative trait loci in synergy permanently improve diastolic dysfunction |
| Q91076523 | Urotensin II, urotensin-related peptide, and their receptor in aortic valve stenosis |
| Q47987007 | Use of ACE Inhibitors for Secondary Prevention |
| Q35542784 | Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry |
| Q104067562 | Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry |
| Q43890671 | Usefulness of self-reported leisure-time physical activity to predict long-term survival in patients with coronary heart disease. |
| Q39251732 | VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice. |
| Q30367111 | Validating Intravascular Imaging with Serial Optical Coherence Tomography and Confocal Fluorescence Microscopy |
| Q30400506 | Validating a bimodal intravascular ultrasound (IVUS) and near-infrared fluorescence (NIRF) catheter for atherosclerotic plaque detection in rabbits. |
| Q92652358 | Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians |
| Q43936573 | Validation of patient-reported warfarin dose in a prospective incident cohort study |
| Q50984731 | Validation of warfarin pharmacogenetic algorithms in clinical practice. |
| Q40279276 | Value of C-Arm Computed Tomography to Evaluate Stent Deployment During Femoro-Popliteal Revascularization |
| Q58129761 | Variants at the APOE /C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol |
| Q53253607 | Vascular biomarkers and surrogates in cardiovascular disease. |
| Q35696297 | Vascular protectants for the treatment of atherosclerosis |
| Q54403391 | Vitamin C and percutaneous coronary intervention: some answers, more questions. |
| Q85517379 | Vulnerable carotid atherosclerotic plaque creation in a Swine model: evaluation of stenosis creation using absorbable and permanent suture in a diabetic dyslipidemic model |
| Q38108537 | What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials |
| Q39633622 | Whole-genome sequencing in French Canadians from Quebec |
| Q48385505 | Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use. |
| Q36398736 | Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry |
| Q44264779 | Women's angiographic vitamin and estrogen trial: design and methods |
| Q58769248 | [ 18 F]-NaF PET/CT Identifies Active Calcification in Carotid Plaque |
| Q56761480 | [18F]-Fluorodeoxyglucose PET/CT imaging as a marker of carotid plaque inflammation: Comparison to immunohistology and relationship to acuity of events |
| Q81961000 | [A new type of medical treatment could lead to regression of aortic valve stenosis] |
| Q90767575 | rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B |
| Q64063691 | β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study |
| Jean-Claude Tardif | wikipedia |
Search more.